Article

Glaucoma-understanding, treatments have evolved over time

The origin of the term glaucoma is disputed. Its meaning through antiquity is also poorly understood. Today there are an increasing number of medications. But as yet we are still in the Dark Ages insofar as the cause of this visually disabling disorder.

Key Points

The authors who described it early on talked about it as a disorder that imparted a green or blue-green color to the pupil, and this idea persisted for centuries. Later, in the writings of the Greeks, a distinction between curable amaurosis with a normal-appearing eye and blindness in an abnormal-looking eye started to appear. It was these eyes that were referred to as having glaucoma.

Innovations

The invention of the ophthalmoscope by Hermann Helmholtz (1821-1894) in 1851, the subsequent appreciation of the damage to the optic nerve that resulted from increased IOP that was first seen by Albrecht von Graefe (1828-1870), and von Graefe's description in 1857 that an iridectomy could be curative in many of these cases would further the understanding of glaucoma at the time.

There were several great innovations along the way to treat glaucoma. In 1875, Ludwig Laquer (1839-1909) first described the use of physo stig mine for the treatment of his own glaucoma. Pressure was first measured by Sir William Bowman in his description of digital pressures counting the elevation as 1-4.

Today, we continue with an increasing number of medications and have some 18 different glaucoma medicines that can be used. In addition, we have a variety of surgical procedures, including the use of lasers. Each of these modalities are helpful in our treatment of the pressure findings in glaucoma, but as yet we are still in the Dark Ages insofar as the cause of this visually disabling disorder.

Norman B. Medow, MD, FACS, is director of pediatric ophthalmology at Manhattan Eye, Ear & Throat Hospital and chairman of the Museum of Vision at the Foundation of the American Academy of Ophthalmology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.